Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial
Pau Montesinos, William Blum, P. Brent Ferrell, Gail J. Roboz et al.
Citations
12 citations
Journal
Journal of Hematology & Oncology
Topics
Acute Myeloid Leukemia Research
Field-Weighted Citation Impact (FWCI)
21.24
article
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial
Pau Montesinos, William Blum, P. Brent Ferrell, Gail J. Roboz, Justin M. Watts, Jörge E. Cortes, Stéphane de Botton, Alice S. Mims, Hua Tian, Jay Yang, Aaron Sheppard, Gary J. Schiller, Eunice S. Wang, Maria R. Baer, Karen W L Yee, Brian A. Jonas, Antonio Curti
article en
12 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal of Hematology & OncologyVol. 18(1)
Institutions
University of Maryland, Baltimore (US), Roswell Park Comprehensive Cancer Center (US), Emory Healthcare (US), University of Miami (US), Cornell University (US), Augusta University (US), Ronald Reagan UCLA Medical Center (US), Institut Gustave Roussy (FR), Princess Margaret Cancer Centre (CA), Hospital Universitari i Politècnic La Fe (ES), Augusta University Health (US), The Barbara Ann Karmanos Cancer Institute (US), Azienda USL di Bologna (IT), National Cancer Center of Georgia (GE), Sylvester Comprehensive Cancer Center (US), Rigel (United States) (US), Winship Cancer Institute, The Ohio State University (US), University of California, Davis (US), Vanderbilt University Medical Center (US)
Funders
Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Leukemia and Lymphoma Society, Celgene, Jazz Pharmaceuticals, Foghorn Therapeutics, Syndax Pharmaceuticals, Daiichi-Sankyo, Astellas Pharma, Servier, Genentech